NCT07176117 - Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants | Biotech Hunter

Enrollment

422

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

June 30, 2031

Conditions

Respiratory Distress Syndrome (Neonatal)Surfactant

Interventions

PROCEDURE

Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA)

A single dose of surfactant will be given via Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA). A supraglottic airway device will be used as a standardized procedure for surfactant administration via SALSA using an AirLife Air-Q.

PROCEDURE

Continuous Positive Airway Pressure (CPAP)

Infants to receive continuation of non-invasive respiratory support will remain on continuous positive airway pressure (CPAP).

Trial Locations (3)

91911

Sharp Chula Vista Medical Center, Chula Vista

91942

Sharp Grossmont Hospital, La Mesa

92123

Sharp Mary Birch Hospital for Women & Newborns, San Diego